"Cancer"

Data from a study of a cancer vaccine combined with a PD-1 immune checkpoint inhibitor has recently been released, and the treatment has increased the survival of patients with advanced colorectal cancer by more than three times, with some patients surviving for more than 22 months so far.

The University of Washington Medical Center owns and manages CUMG and the Seattle Cancer Care Alliance, which is a joint venture between the University of Washington Medical Center, Fred Hutchinson Cancer Research Center and Seattle Children's Hospital.

The Moffitt Cancer Center & Research Institute is a non-profit cancer treatment and research centre established in 1981 by the Florida Legislature and opened on the campus of the University of South Florida in October 1986.

Elahere, the first antibody-coupled drug (ADC) for refractory ovarian cancer, has received accelerated approval from the FDA, resulting in substantial tumour shrinkage in 31.7% of patients and complete tumour disappearance in 4.8%.

Researchers at the Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai have now identified a new treatment that promises to help cancer patients with bone marrow transplants manage side effects better than current standard therapies, making the treatment more effective and safer.

The US FDA approved the ADC drug gosatumumab (Trodelvy) for the treatment of patients with hormone receptor-positive, HER2-negative breast cancer. In the trial, the drug significantly extended the overall survival of patients and reduced the risk of death by 21%.

Every disease has a cause, and we are all sick because of various factors. Understanding the causes of diseases can help us to prevent them, which will help our health a lot.

In recent years, scientists have begun to look at "transforming" cancer cells from life-threatening bad actors to help fight cancer.

Japan's top-ranked cancer treatment hospital

According to data from cohort 17 of the phase 1b COSMIC-021 trial (NCT03170960), the combination therapy of cabozantinib and atelizumab, at a mean follow-up of 25.9 months, 17% of the 30 patients in cohort 17 had significant tumour shrinkage or disappearance, giving an overall disease control rate of 60% when those with stable lesions were added. 5 patients with tumours in remission All of the patients whose tumours had shrunk by at least 30%.